Dermata Therapeutics, Inc. (DRMA) vs Xenetic Biosciences, Inc. (XBIO)
A side-by-side comparison of Dermata Therapeutics, Inc. and Xenetic Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DRMA
Dermata Therapeutics, Inc.
$1.13HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
XBIO
Xenetic Biosciences, Inc.
$2.12HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — DRMA vs XBIO
growth of $100 · dividends reinvested · last 5yDRMA -100.0% (-84.5%/yr)XBIO -93.2% (-41.6%/yr)XBIO compounded faster over this window
Log scale — wide-divergence pair
DRMA XBIO
DRMA vs XBIO: by the numbers
- •XBIO is the larger company ($5M vs $5M market cap).
- •Both run net losses; DRMA's is the smaller (0.00% vs -75.90% net margin).
Metrics side by side
Valuation
| Metric | DRMA | XBIO |
|---|---|---|
| P/S ratio | N/A | 1.49 |
| P/B ratio | 1.30 | 0.80 |
Profitability
| Metric | DRMA | XBIO |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -95.23% |
| Net margin | 0.00% | -75.90% |
| ROE | -239.95% | -40.76% |
| ROIC | -246.61% | -43.50% |
Growth (annualized)
| Metric | DRMA | XBIO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 34.31% |
| Total return CAGR (5Y) | -83.90% | -34.54% |
Frequently asked
- How have DRMA and XBIO total returns compared?
- Over the past 5 years, DRMA delivered -83.90% and XBIO delivered -34.54% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Dermata Therapeutics ROEXenetic Biosciences ROEDermata Therapeutics operating marginXenetic Biosciences operating marginDermata Therapeutics revenue growthXenetic Biosciences revenue growthDermata Therapeutics free cash flowXenetic Biosciences free cash flow
Dermata Therapeutics & Xenetic Biosciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.